FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA OKs New Skyrizi Indication

[ Price : $8.95]

FDA approves a new ulcerative colitis indication for AbbVies Skyrizi.

Target Health ANDA Withdrawals Notice Corrected

[ Price : $8.95]

Federal Register notice: FDA corrects a 3/29 notice on the approval withdrawals of 30 ANDAs from multiple applicants due to Target...

Human User Safety in Animal Drugs Guidance

[ Price : $8.95]

FDA publishes a guidance explaining how CVM assesses human user safety in applicable animal drug applications.

Synapse Labs Studies Unacceptable: FDA

[ Price : $8.95]

FDA tells NDA and ANDA sponsors they must repeat clinical and bioanalytical studies conducted for their applications by Synapse La...

Praise, Suggestions for RWE Studies Guidance

[ Price : $8.95]

Six stakeholders express appreciation for and suggest improvements to an FDA draft guidance on using real-world evidence in non-in...

FDA OKs Major Yescarta, Tecartus REMS Changes

[ Price : $8.95]

FDA approves changes to the REMS for Kites lymphoma treatments Yescarta and Tecartus.

4 Observations in Dr. Reddys Inspection

[ Price : $8.95]

FDA releases the form FDA-483 issued with four observations following an inspection at the Dr. Reddys active pharmaceutical ingred...

Inspection Delay, Denial, Limit, Refusal Guidance

[ Price : $8.95]

FDA publishes a guidance describing the behaviors the agency sees as delaying, denying, limiting, or refusing a drug or device ins...

FDA Abandoning Biosimilar Switching Studies

[ Price : $8.95]

FDA issues a draft guidance indicating that it is moving away from recommending switching studies to support an interchangeability...

20 No-Longer-Marketed ANDAs Withdrawn

[ Price : $8.95]

Federal Register notice: FDA withdraws approval of 20 ANDAs from multiple applicants after they notified the agency that the drug ...